Article
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
Oncogene - 16 Jun 2016
Schabath M B, Welsh E A, Fulp W J, Chen L, Teer J K, Thompson Z J, Engel B E, Xie M, Berglund A E, Creelan B C, Antonia S J, Gray J E, Eschrich S A, Chen D-T, Cress W D, Haura E B, Beg A A
Abstract excerpt
While mutations in the KRAS oncogene are among the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to therapy. We hypothesized that the presence of commonly co-occurring mutations in STK11 and TP53 tumor suppressors may represent a significant source of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.